Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017
Authors:
- 1 March 2018
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 16 (1) , 147-164
Abstract
Monoclonal antibodies targeting tumor necrosis factor-alpha, integrin molecules, and interleukin-12/23 have become backbone therapies for Crohn’s disease and ulcerative colitis. While clinically effective, these biologic therapies come with significant expense, contributing to overall healthcare spending in the USA. Biosimilars have the potential to significantly reduce expenditures secondary to the use of biologic medications such as infliximab and adalimumab, though their complicated manufacturing process results in inherent differences in structure when compared to the originator compounds. In this article, we review the available literature regarding biosimilars in IBD.Keywords
This publication has 42 references indexed in Scilit:
- Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case SeriesDigestive Diseases and Sciences, 2014
- The challenge of indication extrapolation for infliximab biosimilarsBiologicals, 2014
- Biosimilars 101: considerations for U.S. oncologists in clinical practiceCancer Medicine, 2014
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN studyGut, 2012
- Economic burden associated with the use of generic antiepileptic drugs in the United StatesEpilepsy & Behavior, 2010
- Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trialGastroenterology, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002